DexCom makes continuous glucose monitors (CGMs) that let diabetics track blood sugar in real time without finger-prick tests—think a wearable sensor that beams data to a phone.
Money comes from selling CGM systems and sensors, with gross margins around 62% and net margins near 20%—recurring revenue from disposable sensors drives the model.
DexCom's integrated hardware, software, and clinical data create switching costs for patients and doctors, but Abbott's FreeStyle Libre is aggressively undercutting on price and expanding access, eroding DexCom's lead.
Hold (sector percentile 47) — value B, growth B, profitability B+, momentum C+, revisions B-. Updated daily, sector-relative, identical for every user.
Key events, in time order
Stock at 52-week high and above 20-day MA, reflecting market's positive response to Q2 results and raised guidance
Q2 revenue of $1.31B beat estimates, US up 11%, international strong, full-year guidance raised.
Institutional stake up 1.3% in Q1, per SEC filing
First company chosen for FDA pilot, signaling regulatory endorsement of its digital health devices
Regulatory approval extends wear time, boosting North American market position
Q1 2026 worldwide revenue of $1.19 billion, up 15% reported and 12% organic versus 2025
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
